Clinical trial
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With…
NCT00369824 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00369824 |
|---|---|
| Title | Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects |
| Official title | A Randomized, Open Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine Co-administered Intramuscularly With Boostrix® and/or Menactra™ in Healthy Female Subjects Aged 11-18 Years |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM |
| Enrollment | 1,330 |
| Start date | Sep 26, 2006 |
| Primary completion | Nov 22, 2007 |
| Completion | Feb 13, 2008 |
| First posted | Aug 29, 2006 |
| Last update posted | Jul 20, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: